**Appendix 2. Baseline Patient Characteristics Stratified by Indication and Treatment History: Patients who Completed the Study**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Characteristic | Indication; no. (%) of patientsa | | | | | | | | | | | |
| Adult focal spasticity | | Blepharospasm | | Cerebral palsy | | Cervical dystonia | | Hemifacial spasm | | Hyperhidrosis | |
| naïve | maint | naïve | maint | naïve | maint | naïve | maint | naïve | maint | naïve | maint |
|  | (N=46) | (N=122) | (N=10) | (N=38) | (N=0) | (N=3) | (N=12) | (N=126) | (N=23) | (N=53) | (N=8) | (N=14) |
| Age  *years, mean* ±*SD* | 55±17 | 54±16 | 66±11 | 63±12 | - | 15±1 | 60±13 | 57±11 | 64±11 | 66±11 | 36±10 | 36±8 |
| *Diff (95%CI)b* | 0.9 (-5.0, 6.7) | | 2.3 (-6.4, 10.9) | | - | | -2.8 (-5.8, 11.5) | | -2.1 (-7.6, 3.3) | | -0.1 (-9.3, 9.1) | |
| Gender  *Female*  *Male* | 25 (54)  21 (46) | 76 (62)  46 (38) | 6 (60)  4 (40) | 21 (55)  17 (45) | 0 (0)  0 (0) | 1 (33)  2 (67) | 9 (75)  3 (25) | 96 (76)  30 (24) | 16 (70)  7 (30) | 38 (72)  15 (28) | 6 (75)  2 (25) | 12 (86)  2 (14) |
| Race  *White/Caucasian*  *Otherc* | 42 (91)  4 (9) | 110 (90)  12 (10) | 9 (90)  1 (10) | 37 (97)  1 (3) | 0 (0)  0 (0) | 3 (100)  0 (0) | 12 (100)  0 (0) | 124 (98)  2 (2) | 18 (78)  5 (22) | 50 (94)  3 (6) | 8 (100)  0 (0) | 13 (93)  1 (7) |
| Employment  *Full-time*  *Part-time*  *Retired*  *Self-Employed*  *Unemployed*  *Other* | 3 (7)  2 (4)  19 (41)  2 (4)  15 (33)  5 (11) | 8 (7)  10 (8)  35 (29)  3 (2)  47 (38)  19 (16) | 2 (20)  1 (10)  7 (70)  0 (0)  0 (0)  0 (0) | 9 (24)  5 (13)  21 (55)  0 (0)  1 (3)  2 (5) | 0 (0)  0 (0)  0 (0)  0 (0)  0 (0)  0 (0) | 0 (0)  0 (0)  0 (0)  0 (0)  0 (0)  3 (100) | 3 (25)  1 (8)  4 (33)  0 (0)  2 (17)  2 (17) | 42 (33)  11 (9)  40 (32)  8 (6)  22 (18)  3 (2) | 3 (13)  2 (9)  15 (65)  2 (9)  1 (4)  0 (0) | 11 (21)  3 (6)  32 (60)  0 (0)  2 (4)  5 (9) | 6 (75)  0 (0)  0 (0)  0 (0)  1 (13)  1 (12) | 8 (57)  2 (14)  0 (0)  2 (14)  0 (0)  2 (15) |
| Time since diagnosis  *months, median (range)* | 35 (2-736) | 76 (5-786) | 10 (4-44) | 72  (20-261) | - - | 181 (179-196) | 10 (5-119) | 87 (8-589) | 12 (3-201) | 93 (8-507) | 52 (5-376) | 41 (11-282) |
| Time since first treatment prior to study entryd  *months, mean (SD)* | NA | 31.7±28.2 | NA | 77.5±59.5 | NA | 47.0±43.3 | NA | 73.6±58.8 | NA | 77.0±59.3 | NA | 23.8±17.8 |
| Number of injections per yearc  *number, mean (SD)* | NA | 3.4±0.9 | NA | 3.6±1.0 | NA | 2.0±1.0 | NA | 3.5±0.9 | NA | 3.5±0.7 | NA | 1.8±0.6 |

CI=confidence interval, Diff=difference, maint=maintenance; SD=standard deviation

a Unless otherwise indicated

b Difference calculated for naïve minus maintenance groups, for means

c Includes the following which were each ≤5% of the population: Aboriginal, Arab/West Asian, Black, Chinese, Filipino, Japanese, Korean, Latin American, South Asian, South East Asian, and/or those categorized as “other”, except for the cerebral palsy cohort where South Asian accounted for 9% (n=2) of the maintenance population

d OnabotulinumtoxinA treatment characteristics prior to entering study; only applicable to maintenance patients